** Shares of Cochlear COH.AX fall as much as 1.3% to A$309.090
** Shares of the healthcare technology co set for their weakest week since December 9, 2024, if losses hold
** The priciest stock in ASX is tracking losses seen by the country's healthcare sub-index .AXHJ, which is down 0.7%
** UBS hikes stock's price target to A$270 from A$265, retains "sell" rating
** Brokerage made changes to their foreign exchange estimates, underlying assumptions are unchanged
** Three of 15 analysts rate the stock "buy" or higher, 10 "hold" and two "sell"; their median PT is A$305.00 – LSEG data
** Stock fell 8.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。